Index

Note: Page numbers of article titles are in **boldface** type.

A

A Placebo-Controlled, Double Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (ATHENA), 993

A Trial of Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure (ATOMIC-AHF), 949

N-Acetyl-β-D-glucosaminidase, as biomarker, 966

ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbsartan for Prevention of Vascular Events) trial, 995–996

Acute Infarction Ramipril Efficiency (AIRE), 919

Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF), 945

Adipositas cordis, 980

AF-CHR (Atrial Fibrillation in Congestive Heart Failure) trial, 990–991

African-American Heart Failure Trial, 928–929

AIRE (Acute Infarction Ramipril Efficiency), 919

Albuminuria, as biomarker, 966

Aldosterone, in heart failure, 884–885, 894

Aldosterone antagonists, 897–898, 920, 924–925

Amiodarone, for atrial fibrillation, 990

ANDROMEDA (Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluation Morbidity Decrease), 993

Anemia, 979–980

Angioedema, from angiotensin-converting enzyme inhibitors, 923

Angiotensin, in heart failure, 884–885, 894

Angiotensin receptor blockers, 897–898, 920, 923–924, 995

Angiotensin-converting enzyme, in heart failure, 884–885

Angiotensin-converting enzyme inhibitors, 884–885, 898, 918–923, 963

adverse effects of, 921–923

dosage of, 919–921

for atrial fibrillation, 995

in diabetes, 977

safety of, 921–923

trials of, 918–919

Anthracyclines, cardiomyopathy due to, 1003–1005

Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluation Morbidity Decrease (ANDROMEDA), 993

Antiplatelet therapy, for atrial fibrillation, 996

Antithrombosis therapy, for atrial fibrillation, 995–996

Apnea, sleep, 979

ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure), 945
Ascites, 961
Aspirin, for atrial fibrillation, 996
ATHENA (A Placebo-Controlled, Double Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients With Atrial Fibrillation/Atrial Flutter), 993
ATOMIC-AHF (A Trial of Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) trial, 949
Atrial fibrillation, 987–1000
  - pathophysiology of, 989–990
  - prognosis and, 988–989
  - treatment of
    - non-antirhythmic therapeutic alternatives, 994–999
    - nonpharmacologic, 992–993
    - rate-control approaches, 990–993
    - rhythm control approaches, 993–994
    - target heart rate in, 992
Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE) trial, 995–996
Atrial Fibrillation in Congestive Heart Failure (AF-CHF) trial, 990–991
Atrial natriuretic peptide, 885–886, 902–905
Atrioventricular nodal ablation, for atrial fibrillation, 992–993

B
Baroreceptors, in heart failure, 883–884
BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) study, 905
BEAUTIFUL (Morbidity-Mortality Evaluation of the / Inhibitor Ivabradine in Patients With Coronary Disease and Left Ventricular Dysfunction), 992
Beta blockers, 898, 920, 925–927
  - for atrial fibrillation, 991
  - inotropic therapy as bridge to, 950
Biomarkers
  - for heart failure, 901–913, 963–964, 1010
    - cardiac troponins, 905–906
    - cardiorenal, 908–910
    - galectin-3, 907–908
    - natriuretic peptides, 902–905
    - ST2, 907
  - for kidney dysfunction, 964–966
Bisoprolol, 926, 991
Blood urea nitrogen, as biomarker, 964
Brain natriuretic peptide, as biomarker, 885–886, 894, 903, 905
Braking phenomenon, diuretic, 937
Breast cancer therapies, cardiomyopathy due to, 1001–1019
  - agents used for, 1002–1003
  - anthracycline, 1003–1005
  - balancing outcomes in, 1012–1013
  - case study of, 1001–1002, 1014
  - diagnosis of, 1006–1010
  - HER2, 1005–1006
recommendations for, 1013
surveillance for, 1010–1012
treatment of, 1010–1013
Breathing, sleep-disordered, 979
Breathing Not Properly study, 903
B-type natriuretic peptide, in heart failure, 885–886, 894, 903, 905
Bumetanide, pharmacokinetics of, 934–935

C

CAFE-II trial, 990
Calcium Sensitizer or Inotrope of None in Low Output Heart Failure (CASINO), 949
Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure (CANPAP) study, 979
Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) trial, 988
CANPAP (Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure) study, 979
Captopril, 919–920
Cardiac Insufficiency Bisoprolol Study (CIBIS), 926
Cardiac Resynchronization in Heart Failure (CARE-HF) trial, 908
Cardiomyopathy
	from breast cancer therapies, 1001–1019
tachycardia-induced, 989–990
Cardiorenal syndrome, 939, 955–956
CARE-HF (Cardiac Resynchronization in Heart Failure) trial, 908
Carvedilol, 926, 928, 991, 1012
Carvedilol Or Metoprolol European Trial (COMET), 988–989, 992
Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study, 926
CASINO (Calcium Sensitizer or Inotrope or None in Low Output Heart Failure), 949
CASTLE-AF (Catheter Ablation vs. Standard Conventional Treatment in Patients with Left Ventricular Dysfunction and Atrial Fibrillation), 994
Central sleep apnea, 979
CF-STAT (Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy), 990
CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) trial, 988
Chemotherapy. See Breast cancer therapies.
Chronic Kidney Disease Epidemiology Collaboration equations, 957
Chronic obstructive pulmonary disease, 978–979
CIBIS (Cardiac Insufficiency Bisoprolol Study), 926
Clopidogrel, 995
Cockcroft-Gault formula, 957
Coenzyme Q10, for hyperlipidemia, 978
Cognitive dysfunction, 980–981
COMET (Carvedilol Or Metoprolol European Trial), 988–989, 992
Comorbid conditions, 975–985
anemia, 979–980
chronic obstructive pulmonary disease, 978–979
dementia, 980–981
depression, 980–981
diabetes mellitus, 976–977
Comorbid (continued)

- epidemiology of, 975–976
- hyperlipidemia, 978
- hypertension, 977–978
- obesity, 980
- sleep-disordered breathing, 979

Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy (CF-STAT), 990

CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study), 919

Continuous positive airway pressure, for sleep-disordered breathing, 979

Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial, 978

Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), 919

COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival) study, 926

CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) trial, 978

Cough, from angiotensin-converting enzyme inhibitors, 922

Cox-Maze procedure, for atrial fibrillation, 994

C-reactive protein, as biomarker, 964

C-type natriuretic peptide, as biomarker, 903, 905

Cystatin C, as biomarker, 908–909, 964

Cytokines, as biomarkers, 964

D

Dabigatran, for atrial fibrillation, 995

Danish Investigations and Arrhythmia ON Dofetilide (DIAMOND) study, 976, 990

Daunorubicin, cardiomyopathy due to, 1003–1005

Dementia, 980–981

Depression, 980–981

Dexrazoxane, 1005, 1012

Diabetes mellitus, 976–977

DIAMOND (Danish Investigations and Arrhythmia ON Dofetilide) study, 976, 990

Diastolic heart failure

- definition of, 891–892
- diagnosis of, 897
- pathophysiology of, 895–898

Digoxin, 991

Diuretic Strategies in patients with Acute Decompensated Heart Failure (DOSE) trial, 936, 945–946

Diuretics, 898, 933–942

- adverse effects of, 938–939
- dosing of, 936
- for kidney dysfunction, 961–963
- guidelines for, 939
- in combination therapy, 937
- in kidney disease, 935
- in liver disease, 935
- intravenous, 936
- mechanism of action of, 933–934
- newer agents for, 939–940
- pharmacodynamics of, 935
- resistance to, 937–938

Dizziness, from angiotensin-converting enzyme inhibitors, 921–922
Dobutamine, 947
Dofetilide, 990
Dopamine, 894, 946–947
Doppler imaging, for breast cancer-related cardiomyopathy, 1007–1009
DOSE (Diuretic Strategies in patients with Acute Decompensated Heart Failure) trial, 936, 945
Doxorubicin, cardiomyopathy due to, 1003–1005
Dronedarone, 993
Dyspnea, 897
Dyssynchrony, mechanical, in heart failure, 895

E
Echocardiography, 893, 897–898, 1006–1009
Edema, 897
Ejection fraction, 892
Enalapril, 919–920, 1012
Enoximone, 948–949
Epirubicin, cardiomyopathy due to, 1003–1005
Eplerenone, 924–925
Erythropoietin stimulants, for anemia, 980
ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness), 959, 961–962

F
FAIR-HF (Ferric carboxymaltose Assessment in patients with IRon deficiency and chronic Heart Failure with and without anemia) trial, 980
Fatigue, from beta blockers, 928
Fatty acid-binding protein, as biomarker, 966
Ferric carboxymaltose Assessment in patients with IRon deficiency and chronic Heart Failure with and without anemia (FAIR-HF) trial, 980
Flosequinan, 948–949
Fluid retention, from beta blockers, 928
Fosinopril, 920
Furosemide
doing of, 936
in kidney dysfunction, 935
pharmacokinetics of, 934–935

G
Galectin-3, as biomarker, 907–908
GALLANT trial, 909–910
GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Heart Failure) trial, 978
Glomerular filtration rate, in kidney dysfunction, 957–958
Gout, from diuretics, 938–939
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Heart Failure (GISSI-HF) trial, 978
Heart, transplantation of, inotropic therapy as bridge to, 950
Heart failure, 881–890
- atrial fibrillation in, 987–1000
- biomarkers for, 901–913, 963–966, 1010
- comorbid conditions in, 975–985
- definitions of, 891–892
- diastolic, 895–898
- epidemiology of, 881–882, 987
- evaluation of, 943–945
- in breast cancer therapies, 1001–1014
- kidney dysfunction in, 955–974
- pathophysiology of, 882–887, 891–899
- prognosis for, atrial fibrillation and, 988–989
- stages of, 916
- systolic, 891–895, 897
- treatment of, 897–898
  - aldosterone antagonists, 897–898, 920, 924–925
  - algorithm for, 917
  - angiotensin receptor blockers, 897–898, 920, 923–924
  - angiotensin-converting enzyme inhibitors. See Angiotensin-converting enzyme inhibitors.
  - beta blockers, 898, 920, 925–927
  - diuretics, 933–942
  - evidence-based, 915–931
  - natriuretic peptide-guided, 903, 905
  - palliative, 950–951
  - vasodilators, 928–929, 945
Heart Failure Society of America
guidelines for diuretics, 939
heart failure definition of, 944
Hemodynamics
- in heart failure, 894–897
- in kidney dysfunction, 961
HER2, cardiomyopathy due to, 1005–1006
Herceptin, cardiomyopathy due to, 1005–1006
Hydralazine, 898, 920, 928–929
Hydrochlorothiazide
- in combination therapy, 937
- pharmacokinetics of, 934–935
Hyperkalemia
- from angiotensin receptor blockers, 925
- from angiotensin-converting enzyme inhibitors, 922
Hyperlipidemia, 978
Hypertension, 977–978
Hyperuricemia, from diuretics, 938–939
Hypokalemia, from diuretics, 938
Hyponatremia, from diuretics, 938–939
Hypoperfusion
- from beta blockers, 928
from diuretics, 938
Hypotension, from angiotensin-converting enzyme inhibitors, 921–922

I
Ibopamine, 988
Implantable cardioverter defibrillator, 898
Inflammation, in heart failure, 963–964
Inotropic therapy, 943–954
   as bridge to beta-blockade, 950
   as bridge to transplantation, 950
   challenges in, 951
   dobutamine, 947
   dopamine, 946–947
   failed, 948–949
   for palliative care, 950–951
   home, 950–951
   investigative, 949
   milrinone, 947–948
   options for, 945–946
Interleukin(s), as biomarkers, 964
Interleukin-1 receptors, as biomarkers, 907
Iron supplementation, for anemia, 980
Iron-deficiency anemia, 979–980
Isosorbide dinitrate, 898, 920, 928–929
Italian Research Emergency Department (RED) study, 903
Ivabradine, 992

K
Kidney, dysfunction of, 955–974
   biomarkers generated by, 908–910
   cardiorenal syndrome, 939, 955–956
   chronic, 957–958
   diuretics usage in, 935
   epidemiology of, 958
   from angiotensin-converting enzyme inhibitors, 922
   from diuretics, 939
   markers of, 964–966
   prognosis for, 958
   stages of, 958
   worsening, 958–964
KIM-1 (kidney injury molecule 1), as biomarker, 910, 965–966

L
Lapatinib, cardiomyopathy due to, 1005–1006
Left ventricular assist device, 898
Levosimendan, 949
LIDO (Livosimendan Infusion versus Dobutamine), 949
Lipocalins, as biomarkers, 909–910, 965
Lisinopril, 920
Liver, dysfunction of, diuretics in, 935
Loop diuretics, pharmacokinetics of, 934–935
Low cardiac output syndrome, treatment of, inotropes for, 945–951

M
Magnetic resonance imaging
  for breast cancer-related cardiomyopathy, 1009–1010
  for heart failure, 893
Mechanical dyssynchrony, in heart failure, 895
Mechanoreceptors, in heart failure, 883–884
MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure), 926
Metolazone
  in combination therapy, 937
  pharmacokinetics of, 934–935
Metoprolol, 926, 988–989, 991
Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), 926
Milrinone, 947–948
Modification of Diet in Renal Disease formula, 957
Morbidity-Mortality Evaluation of the β Inhibitor Ivabradine in Patients With Coronary Disease and Left Ventricular Dysfunction (BEAUTIFUL), 992
Multi-gated radionuclide angiography, for breast cancer-related cardiomyopathy, 1007
Myocardial strain echocardiography, for breast cancer-related cardiomyopathy, 1007–1009

N
Natriuretic peptides
  as biomarkers, 902–905
  in heart failure, 885–886, 894
Nesiritide, 945–946
Neurohormones
  in heart failure, 883–887, 894, 896
  in kidney dysfunction, 959–961
Neutrophil gelatinase-associated lipocalin-2 (NGAL), as biomarker, 909–910, 965
Nitroglycerin, 945–946
Norepinephrine, in heart failure, 883–884, 894, 926
N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study, 903
Nuclear imaging, for breast cancer-related cardiomyopathy, 1009

O
Obesity, 980
Obstructive sleep apnea, 979
Omecamtiv mecarbil, 949
Omega-3 fatty acids, for atrial fibrillation, 994
OPTIME (The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure), 945, 948, 964
Orthopnea, 897
Ototoxicity, from diuretics, 939

P
PABA-CHF (Pulmonary Vein Antrum Isolation vs AV Node Ablation With Bi-Ventricular Pacing for Treatment of Atrial Fibrillation with Patients with Congestive Heart Failure), 994
Pacemaker, for atrial fibrillation, 992–993
Palliative care, 950–951
Parasympathetic nervous system, in atrial fibrillation, 990
Perindopril, 920
Pertubumab, cardiomyopathy due to, 1005–1006
Phosphodiesterase inhibitors, 898
Pimobendan, 948–949
Positron emission tomography, for breast cancer-related cardiomyopathy, 1009
PRECEDENT (Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy) study, 947
PRIDE (N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department) study, 903
PRIME (Prospective Randomized Study of Ibopamine on Mortality and Efficacy) study, 988
Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy (PRECEDENT) study, 947
Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME) study, 988
PROTECT study, 905
Pulmonary Vein Antrum Isolation vs AV Node Ablation With Bi-Ventricular Pacing for Treatment of Atrial Fibrillation with Patients with Congestive Heart Failure (PABA-CHF), 994
Pulmonary venous pressure, 894, 896–897

Q
Quinapril, 920

R
RACE (Rate-Control Efficacy in Permanent Atrial Fibrillation) trial, 990–991
Radiofrequency ablation, for atrial fibrillation, 992–994
RALES (Randomized Aldactone Evaluation Study), 924
Ramipril, 919–920
Randomized Aldactone Evaluation Study (RALES), 924
Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, for atrial fibrillation, 995
Ranolazine, for atrial fibrillation, 994
Rate-Control Efficacy in Permanent Atrial Fibrillation (RACE) trial, 990–991
RED (Italian Research Emergency Department) study, 903
RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, for atrial fibrillation, 995
Renin-angiotensin-aldosterone system
  in heart failure, 884–885, 894, 896
Renin-angiotensin-aldosterone (continued)
  in kidney dysfunction, 959–961
Resynchronization therapy, 898
Rosuvastatin, for hyperlipidemia, 978

S
SAVE (Survival and Ventricular Enlargement) trial, 885–887, 919
Scintigraphy, for breast cancer-related cardiomyopathy, 1009
SHEP (Systolic Hypertension in Elderly) trial, 977
SHIFT (Systolic Heart Failure Treatment with the βi Inhibitor Ivabradine Trial), 992
Sildenafil, 898
Sleep-disordered breathing, 979
SMILE (Survival of Myocardial Infarction Long-term Evaluation), 919
Sodium nitroprusside, 945–946
Sodium retention, in heart failure, 884
SOLVD (Studies of Left Ventricular Dysfunction), 919, 976, 988
Spironolactone, 924–925, 935
ST2, as biomarker, 907
STAMINA-HeFT (Study of Anemia in Heart Failure Trial), 980
Starling function, in systolic heart failure, 892
Statins
  for atrial fibrillation, 994
  for hyperlipidemia, 978
Studies of Left Ventricular Dysfunction (SOLVD), 919, 976, 988
Study of Anemia in Heart Failure Trial (STAMINA-HeFT), 980
Survival and Ventricular Enlargement (SAVE) trial, 885–887, 919
Survival of Myocardial Infarction Long-term Evaluation (SMILE), 919
Sympathetic nervous system
  in atrial fibrillation, 990
  in heart failure, 883–884, 894
  in kidney dysfunction, 960–961
Systolic heart failure, 891–895, 897
Systolic Heart Failure Treatment with the βi Inhibitor Ivabradine Trial (SHIFT), 992
Systolic Hypertension in Elderly (SHEP) trial, 977

T
Tachycardia, 989–990
Tachyphylaxis, from vasodilators, 945–946
The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic
  Heart Failure (OPTIME), 945, 948, 964
Thiazides, pharmacokinetics of, 934–935
Thrombosis, prevention of, in atrial fibrillation, 995–996
Tolvaptan, 939–940
Torsemide, pharmacokinetics of, 934–935
TRACE (Trandolapril Cardiac Evaluation), 919
Trandolapril, 919–920
Trandolapril Cardiac Evaluation (TRACE), 919
Transcatheter atrial fibrillation ablation, 994
Transplantation, cardiac, inotropic therapy as bridge to, 950
Trastuzumab, cardiomyopathy due to, 1005–1006, 1014
Troponins, as biomarkers, 905–906
Tumor necrosis factor-α, as biomarker, 964

V
Vasodilators, 928–929, 945
Vasopressin, in heart failure, 885
Ventricle(s), remodeling of, 886–887
Vesnarinone, 948–949
Veterans Affairs Vasodilator-Heart Failure Trials, 988

W
Wall stress, 892, 895–896
Warfarin, for atrial fibrillation, 995–996
Worsening renal function, 985–964
  definition of, 958–959
  epidemiology of, 958–959
  hemodynamics and, 961
  inflammation in, 963–964
  neurohormones in, 959–961
  prognosis for, 958–959
  treatment of, 961–963

Z
Zofenopril, 919